TY - JOUR T1 - MenB (Bexsero) immunisation side effects in extremely premature infants (<28 weeks) JF - Archives of Disease in Childhood - Fetal and Neonatal Edition JO - Arch Dis Child Fetal Neonatal Ed SP - F85 LP - F85 DO - 10.1136/archdischild-2017-314009 VL - 103 IS - 1 AU - Arindam Mukherjee AU - Devdeep Mukherjee AU - Azita Rajai AU - Srividhya Senthil AU - Ngozi Edi-osagie Y1 - 2018/01/01 UR - http://fn.bmj.com/content/103/1/F85.2.abstract N2 - On 1 September 2015, the UK became the world’s first country to introduce a novel meningococcal B vaccine (Bexsero) into its national childhood immunisation programme. Bexsero is the only market authorised meningococcal B vaccine in the UK. Meningococcal B strains accounts for ~80% of all laboratory confirmed cases of invasive meningococcal disease (IMD) in England and Wales.1 Bexsero is estimated to protect against 73%–88% of the meningococcal B strains causing invasive disease in England and Wales.2 After observing more instances of clinical instability in our immunised neonates following the introduction of the new … ER -